Trial Profile

A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 20 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bimekizumab (Primary) ; Risankizumab (Primary)
Indications Psoriatic arthritis
Focus Registrational; Therapeutic Use
Acronyms BE BOLD
Sponsors UCB Biopharma

Most Recent Events

11 Mar 2026 Primary endpoint (American College of Rheumatology 50 (ACR50) at Week 16) has been met.
11 Mar 2026 Results presented in the UCB pharmaceutical media release.
11 Jun 2025 According to a UCB pharmaceutical media release, company will present data from this study at EULAR 2025 in Barcelona, Spain, 11-14 June.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com